S-Tenatoprazole
Alternative Names: Benatoprazole; S-Tenatoprazole-Na; sTU-199; STU-Na; TU-199Latest Information Update: 12 Dec 2025
At a glance
- Originator Mitsubishi Pharma Corporation
- Developer Abbott Japan; Mitsubishi Pharma Corporation; Negma SAS; Steba Laboratories
- Class Antiulcers; Gastric antisecretories; Imidazoles; Pyridines; Small molecules
- Mechanism of Action Proton pump inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Suspended Gastro-oesophageal reflux
- Discontinued Peptic ulcer; Zollinger-Ellison syndrome
Most Recent Events
- 01 Dec 2025 Mitsubishi Tanabe Pharma Corporation is now called Tanabe Pharma Corporation
- 30 Apr 2018 Discontinued - Phase-I for Gastro-oesophageal reflux in Europe (PO) (Mitsubishi Tanabe Pharma pipeline, May 2018)
- 31 Jul 2017 Phase-I clinical trials in Gastro-oesophageal reflux in Europe (PO) (Mitsubishi Tanabe Pharma Corporation pipeline, July 2017)